PriceTargets.com logo

ALT5 Sigma - ALTS Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.58 As of 12/4/2025 05:00 PM ET
▼ -0.06 (-3.66%)

This chart shows the closing price for ALTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ALT5 Sigma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALTS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for ALT5 Sigma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.58.

This chart shows the closing price for ALTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 polled investment analysts is to sell stock in ALT5 Sigma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/30/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
(Data available from 12/5/2020 forward)

News Sentiment Rating

-0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 8 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 9 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/5/2025
  • 1 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 1 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

ALT5 Sigma logo
ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.
Read More

Today's Range

Now: $1.58
Low: $1.57
High: $1.63

50 Day Range

MA: $2.20
Low: $1.56
High: $3.10

52 Week Range

Now: $1.58
Low: $1.49
High: $10.95

Volume

2,288,300 shs

Average Volume

3,300,703 shs

Market Capitalization

$197.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Frequently Asked Questions

What sell-side analysts currently cover shares of ALT5 Sigma?

The following Wall Street analysts have issued research reports on ALT5 Sigma in the last twelve months: Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for ALTS.

What is the current price target for ALT5 Sigma?

0 Wall Street analysts have set twelve-month price targets for ALT5 Sigma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for ALT5 Sigma in the next year.
View the latest price targets for ALTS.

What is the current consensus analyst rating for ALT5 Sigma?

ALT5 Sigma currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe ALTS will underperform the market and that investors should sell shares of ALT5 Sigma.
View the latest ratings for ALTS.

What other companies compete with ALT5 Sigma?

Other companies that are similar to ALT5 Sigma include CorMedix, Alumis, Valneva, Replimune Group and Arvinas. Learn More about companies similar to ALT5 Sigma.

How do I contact ALT5 Sigma's investor relations team?

ALT5 Sigma's physical mailing address is 325 E. WARM SPRINGS ROAD, SUITE 102, LAS VEGAS, NV, 89119. The company's listed phone number is (702) 997-5968 and its investor relations email address is https://ir.janone.com. The official website for ALT5 Sigma is janone.com. Learn More about contacing ALT5 Sigma investor relations.